Crossmark

Identification of genetically engineered strategies to manipulate nano-platforms presenting immunotherapeutic ligands for alleviating primary ovarian insufficiency progression

Crossref DOI link: https://doi.org/10.1186/s12964-025-02226-8

Published Online: 2025-05-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Guannan

Gu, Yuanyuan

Zhang, Menglei

Ding, Jingxin

Lu, Guanming

Hua, Keqin

Shen, Fang
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No.81771524, No.81471416, No.32060208, No.82260532)

General program of Guangxi Natural Science Foundation (No.2019JJA140071)
License Information

Text and Data Mining valid from 2025-05-28

Version of Record valid from 2025-05-28
More Information

Article History

Received: 3 August 2024

Accepted: 30 April 2025

First Online: 28 May 2025

Declarations

:

: All animal procedures were performed in accordance with the protocol approved by the Institutional Animal Care and Use Committee at the Fudan University (SYXK2020-0032).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below